Anthem among health care’s biggest gainers from federal tax cuts

  • Comments
  • Print

Four of the 20 biggest health-care companies in the Standard & Poor’s 500 Index saw a benefit from the tax overhaul in the fourth quarter.

The biggest gain was pharmaceutical giant Pfizer Inc. with a $11.5 billion benefit, followed by Allergan Plc with $2.78 billion, data compiled by Bloomberg shows.

The difference lies in how the companies decided to deal with their overseas cash.

Most of the firms that saw a tax charge in the quarter no longer considered their overseas earnings permanently reinvested and had to pay a repatriation transition tax. These companies elected to pay off their tax charges over the next eight years.

As a result of the tax changes, U.S. corporations had to recalculate the value of their deferred tax assets or liabilities under the new corporate-tax rate of 21 percent, down from the previous 35 percent. Companies either took a one-time charge or benefit.

The data analysis focused on the 20 largest health-care S&P 500 members measured by market value, out of 61. Among the top 20, the two other companies that recorded a benefit were health insurers UnitedHealth Inc. and Anthem Inc., which have no overseas operations and didn’t pay repatriation tax.

Indianapolis-based Anthem said in February that it reaped a $1.1 billion benefit from the tax cuts and planned to make $1,000 contributions to the retirement accounts of more than 58,000 employees and recent retirees.

For companies like Pfizer that gained access to their overseas cash, Wall Street will scrutinize in the coming quarters how the extra money is allocated. Pfizer CEO Ian Read said during an earnings call on Jan. 30 that the drugmaker will use the tax funds for capital projects in the U.S. and increase pension fund contributions.

As for the companies that took a charge this past quarter, some are looking to spend more.

Johnson & Johnson, which took the biggest tax charge among the 20 companies, with $13.6 billion, has pledged to spend more on research and development going forward.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.